Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kyle Crassini

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Internal Medicine Journal|December 9, 2023
Pathogenesis and management of immune dysfunction secondary to B cell haematological malignanciesKyle Crassini, John Gibson
World Journal of Clinical Cases|August 25, 2015
Targeting chronic lymphocytic leukemia cells in the tumor microenviroment: A review of the in vitro and clinical trials to dateKyle Crassini, Stephen P Mulligan, O Giles Best
Leukemia & Lymphoma|October 21, 2016
Modeling the chronic lymphocytic leukemia microenvironment in vitroKyle Crassini, Yandong Shen, Stephen Mulligan, et al.
Leukemia & Lymphoma|March 26, 2015
The MEK1/2 inhibitor, MEKi-1, induces cell death in chronic lymphocytic leukemia cells under conditions that mimic the tumor microenvironment and is synergistic with fludarabineKyle Crassini, William S Stevenson, Stephen P Mulligan, et al.
British Journal of Haematology|August 1, 2019
Molecular pathogenesis of chronic lymphocytic leukaemiaKyle Crassini, William S Stevenson, Stephen P Mulligan, et al.
British Journal of Haematology|July 7, 2018
The dual inhibitor of the phosphoinositol-3 and PIM kinases, IBL-202, is effective against chronic lymphocytic leukaemia cells under conditions that mimic the hypoxic tumour microenvironmentKyle Crassini, Yandong Shen, Michael O'Dwyer, et al.
British Journal of Haematology|May 17, 2018
MEK1/2 inhibition by binimetinib is effective as a single agent and potentiates the actions of Venetoclax and ABT-737 under conditions that mimic the chronic lymphocytic leukaemia (CLL) tumour microenvironmentKyle Crassini, Yandong Shen, William S Stevenson, et al.
Leukemia & Lymphoma|January 17, 2019
Dual inhibition of MEK1/2 and AKT by binimetinib and MK2206 induces apoptosis of chronic lymphocytic leukemia cells under conditions that mimic the tumor microenvironmentYandong Shen, Kyle Crassini, Suneet Sandhu, et al.
Leukemia & Lymphoma|June 19, 2018
Inhibition of the Raf-1 kinase inhibitory protein (RKIP) by locostatin induces cell death and reduces the CXCR4-mediated migration of chronic lymphocytic leukemia cellsKyle Crassini, Tahni Pyke, Yandong Shen, et al.
Blood Advances|October 21, 2020
IBL-202 is synergistic with venetoclax in CLL under in vitro conditions that mimic the tumor microenvironmentYandong Shen, Kyle Crassini, Narjis Fatima, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Internal Medicine Journal|December 9, 2023
Pathogenesis and management of immune dysfunction secondary to B cell haematological malignanciesKyle Crassini, John Gibson
World Journal of Clinical Cases|August 25, 2015
Targeting chronic lymphocytic leukemia cells in the tumor microenviroment: A review of the in vitro and clinical trials to dateKyle Crassini, Stephen P Mulligan, O Giles Best
Leukemia & Lymphoma|October 21, 2016
Modeling the chronic lymphocytic leukemia microenvironment in vitroKyle Crassini, Yandong Shen, Stephen Mulligan, et al.
Leukemia & Lymphoma|March 26, 2015
The MEK1/2 inhibitor, MEKi-1, induces cell death in chronic lymphocytic leukemia cells under conditions that mimic the tumor microenvironment and is synergistic with fludarabineKyle Crassini, William S Stevenson, Stephen P Mulligan, et al.
British Journal of Haematology|August 1, 2019
Molecular pathogenesis of chronic lymphocytic leukaemiaKyle Crassini, William S Stevenson, Stephen P Mulligan, et al.
British Journal of Haematology|July 7, 2018
The dual inhibitor of the phosphoinositol-3 and PIM kinases, IBL-202, is effective against chronic lymphocytic leukaemia cells under conditions that mimic the hypoxic tumour microenvironmentKyle Crassini, Yandong Shen, Michael O'Dwyer, et al.
British Journal of Haematology|May 17, 2018
MEK1/2 inhibition by binimetinib is effective as a single agent and potentiates the actions of Venetoclax and ABT-737 under conditions that mimic the chronic lymphocytic leukaemia (CLL) tumour microenvironmentKyle Crassini, Yandong Shen, William S Stevenson, et al.
Leukemia & Lymphoma|January 17, 2019
Dual inhibition of MEK1/2 and AKT by binimetinib and MK2206 induces apoptosis of chronic lymphocytic leukemia cells under conditions that mimic the tumor microenvironmentYandong Shen, Kyle Crassini, Suneet Sandhu, et al.
Leukemia & Lymphoma|June 19, 2018
Inhibition of the Raf-1 kinase inhibitory protein (RKIP) by locostatin induces cell death and reduces the CXCR4-mediated migration of chronic lymphocytic leukemia cellsKyle Crassini, Tahni Pyke, Yandong Shen, et al.
Blood Advances|October 21, 2020
IBL-202 is synergistic with venetoclax in CLL under in vitro conditions that mimic the tumor microenvironmentYandong Shen, Kyle Crassini, Narjis Fatima, et al.
Pageof 2